Nephros (NEPH) to Announce Quarterly Earnings on Thursday

Nephros (NASDAQ:NEPH) is projected to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of $0.01 per share and revenue of $4.9940 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Nephros (NASDAQ:NEPH) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. Nephros had a net margin of 4.06% and a return on equity of 7.66%. The company had revenue of $5.21 million for the quarter, compared to analysts’ expectations of $5.02 million. On average, analysts expect Nephros to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Nephros Price Performance

NASDAQ NEPH opened at $3.59 on Wednesday. Nephros has a 12 month low of $2.66 and a 12 month high of $6.42. The company has a market capitalization of $38.99 million, a P/E ratio of 51.29 and a beta of 1.51. The company’s 50 day simple moving average is $3.47 and its 200 day simple moving average is $3.54.

Institutional Trading of Nephros

A number of hedge funds have recently bought and sold shares of the company. Marshall Wace LLP acquired a new position in shares of Nephros in the fourth quarter worth about $107,000. Topline Capital Management LLC raised its holdings in shares of Nephros by 13.1% during the second quarter. Topline Capital Management LLC now owns 477,449 shares of the company’s stock valued at $1,953,000 after acquiring an additional 55,360 shares during the period. Kestra Advisory Services LLC purchased a new stake in shares of Nephros in the 4th quarter valued at approximately $29,000. Dimensional Fund Advisors LP purchased a new stake in shares of Nephros in the 3rd quarter valued at approximately $64,000. Finally, Citadel Advisors LLC lifted its position in shares of Nephros by 39.2% in the 3rd quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock valued at $78,000 after acquiring an additional 4,655 shares in the last quarter. 41.10% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on NEPH. Weiss Ratings upgraded shares of Nephros from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday. Zacks Research upgraded Nephros to a “hold” rating in a research report on Monday, July 20th. Finally, Northland Securities initiated coverage on Nephros in a research note on Friday, July 17th. They set a “market perform” rating and a $4.00 price objective for the company. One research analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $5.00.

About Nephros

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.